Statini

Nigović, Biljana; Fabijanić, Petra; Bačić-Vrca, Vesna

Download
PDF 1 MB

Professional paper - Review paper

Statini

Farmaceutski glasnik, 63 (2007), 5; 315-331. urn:nbn:hr:163:948126

Nigović, Biljana; Fabijanić, Petra; Bačić-Vrca, Vesna

Cite this document

APA 6th Edition

Nigović, B., Fabijanić, P. & Bačić Vrca, V. (2007). Statini. Farmaceutski glasnik, 63. (5), 315-331. Retrieved from https://urn.nsk.hr/urn:nbn:hr:163:948126

MLA 8th Edition

Nigović, Biljana, et al. "Statini." Farmaceutski glasnik, vol. 63, no. 5, 2007, pp. 315-331. https://urn.nsk.hr/urn:nbn:hr:163:948126

Chicago 17th Edition

Nigović, Biljana, Petra Fabijanić and Vesna Bačić Vrca. "Statini." Farmaceutski glasnik 63, no. 5 (2007): 315-331. https://urn.nsk.hr/urn:nbn:hr:163:948126

Harvard

Nigović, B., Fabijanić, P. and Bačić Vrca, V. (2007) 'Statini', Farmaceutski glasnik, 63(5), pp. 315-331. Available at: https://urn.nsk.hr/urn:nbn:hr:163:948126 (Accessed 16 April 2024)

Vancouver

Nigović B, Fabijanić P, Bačić Vrca V. Statini. Farmaceutski glasnik [Internet]. 2007 [cited 2024 April 16];63(5):315-331. Available at: https://urn.nsk.hr/urn:nbn:hr:163:948126

IEEE

B. Nigović, P. Fabijanić and V. Bačić Vrca, "Statini", Farmaceutski glasnik, vol. 63, no. 5, pp. 315-331, 2007. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:163:948126. [Accessed: 16 April 2024]

Cite this item: https://urn.nsk.hr/urn:nbn:hr:163:948126

Please login to the repository to save this object to your list.

Metadata

Title (croatian)	Statini
Author	Biljana Nigović
Author	Petra Fabijanić
Author	Vesna Bačić-Vrca
Author's institution	University of Zagreb Faculty of Pharmacy and Biochemistry (Department of pharmaceutical analysis)
Scientific / art field, discipline and subdiscipline	BIOMEDICINE AND HEALTHCARE Pharmacy Pharmacy
Abstract (english)	Statins represent the most efficient drugs for the treatment of hypercholesterolemia. They competitively inhibit the enzyme HMG-CoA {3-hydroxy-3-methylglutaryl-coenzyme A) reductase, a rate-limiting enzyme, which catalyzes the conversion of hydroxymethylglutarate to mevalonate, an early and rate limiting step in the biosynthesis of cholesterol. The statin class of cholesterol-lowering drugs has been introduced since 1987. Lovastatin is derived from Aspergillus terreus. Whereas simvastatin and pravastatin are produced by semi-synthetic ptocesses, fluvastatin, atorvastatin, pitavastatin and rosuvastatin are completely synthetic compounds. Statins are now among the most frequently prescribed drugs. Although ali statins share a cornrnon rnechanism of action, they differ in terrns of their chernical structures, pharrnacokinetics profiles, and lipid-rnodifying efficacy. Lipid-modifying interventions have been shown to decrease the risk of coronary disease both in patients with hypercholesterolemia and in those with relatively norma! levels of low-density lipoprotein cholesterol. This review surnrnarizes the differences of chemical structures and pharmacokinetic properties of statins and emphasizes their clinically irnportant drug interactions and analytical methods for the determination of statins in biological fluids and pharrnaceutical dosage forms.
Keywords (croatian)
Language	croatian
Publication type	Professional paper - Review paper
Publication status	Published
Peer review	Peer review - domestic
Publication version	Published version
Journal title	Farmaceutski glasnik
Numbering	vol. 63, no. 5, pp. 315-331
p-ISSN	0014-8202
URN:NBN	urn:nbn:hr:163:948126
Publication	2007
Type of resource	Text
Access conditions	Open access
Terms of use
Created on	2020-11-20 15:41:52